Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (587)	7/13/2000 11:13:13 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 743

I would have to check my trades, but on ORCH I only doubled, DNDN less, and SGMO even less still (owing to doubling down a couple of times after the IPO and riding it down down down). Still, overall I'm up about 30% in the last month, which ain't bad. Beats the biotech index. I did go half cash in the wife's account, her return YTD is 260%. My gain is more than twice that, but then I can remember when I was up 9x back there in early March. Ha! Crazy. Anyway, on DNDN--wouldn't matter if I'd held much longer anyway, I only had bought a little. The Seattle Times did an article about the Cowen analyst, William Tanner, who started coverage on DNDN--he admits that he would not have started coverage so early if he did not work for Cowen. "It's a given that if you do the investment banking and get the banking fees, then you'll provide investment coverage". The other two brokerages to begin coverage were also in on the IPO.